Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Arboleda

Pediatric Gastroenterology Miami, FL Medical Doctor

NPI 1033345996 CMS profile 92437

3200 Sw 60Th Ct, Suite 204, Miami, FL 33155

Open in the dashboard

General payments

$4,911

186 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Arboleda of Miami, FL is reported in the CMS Open Payments database as having received $4,911 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,036 50
2024 General $658 28
2023 General $978 24
2022 General $665 20
2021 General $751 27
2020 General $402 17
2019 General $421 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Arboleda
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Richard Arboleda were reported at $1,036. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Richard Arboleda Pediatric Gastroenterology median Middle half National median
2019 $421 $131 $41–$311 $163
2020 $402 $79 $23–$223 $114
2021 $751 $104 $32–$321 $132
2022 $665 $125 $37–$331 $149
2023 $978 $169 $55–$440 $160
2024 $658 $196 $73–$563 $164
2025 $1,036 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $836 47 payments
  2. Janssen Scientific Affairs, LLC $564 6 payments
  3. AbbVie, Inc. $501 23 payments
  4. Genzyme Corporation $450 13 payments
  5. Nestle HealthCare Nutrition Inc. $431 10 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $375 17 payments
  7. Ipsen Biopharmaceuticals, Inc $322 18 payments
  8. Regeneron Healthcare Solutions, Inc. $262 8 payments
  9. Mirum Pharmaceuticals, Inc. $183 6 payments
  10. Medtronic, Inc. $150 1 payment
  11. Other $837 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,835 185 payments
  2. Education $76 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $1,133 40 payments
  2. ZENPEP $507 14 payments
  3. HUMIRA $356 20 payments
  4. DUPIXENT Inflammation And Immunology $345 7 payments
  5. Bylvay $334 19 payments
  6. DUPIXENT Immunology $309 11 payments
  7. TREMFYA $250 12 payments
  8. GATTEX $184 9 payments
  9. Livmarli $183 6 payments
  10. REMICADE $182 4 payments
  11. Other $1,110 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record